FT Global Pharmaceutical and Biotechnology Conference

From 11/11/2019 to 12/11/2019

Disruption and transformation will continue to be the focus of life science leaders in 2019 and beyond. 

Pricing pressures in the US and a growing number of markets globally have already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of the industry’s underlying economic and funding model.

With a host of ‘new entrants’ in the shape of big tech and consumer-centric start-ups nibbling at pharma’s heels in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on forging relationships with patients sustained on trust, and building new business models for the future.

London, UK

More information


Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.